| 1. |
- Ghosh, Amar, et al.
(författare)
-
Green synthesis of silver nanoparticles and its applications as sensor, catalyst, and antibacterial agent
- 2023
-
Ingår i: Materials Today. - : Elsevier. - 2214-7853.
-
Tidskriftsartikel (refereegranskat)abstract
- We have reported for the first time a solvated electron mediated reduction of silver ion (Ag+) in presence of extract of Murraya koenigii (Mk) leaf as a surfactant to produce silver nanoparticles (AgNPs). Synthesized NPs show efficient ascorbic acid sensing at the µM range along with selective detection of different metal ions due to the presence of different biomolecules on the surface which are present in the extract. Synthesized nontoxic AgNPs will also exhibit proficient photocatalytic behavior for the degradation of toxic dyes due to the effective coupling between surface plasmon of AgNPs and the excited state continuum of the dye fluorophores. AgNPs will also exhibit substantial antibacterial activities. Altogether, our biosynthesized nontoxic NPs could be effectively used as both chemical and biosensor, catalyst as well as antibacterial agent.
|
|
| 2. |
- Mukherjee, Subhankar, et al.
(författare)
-
Sensory development for heavy metal detection: A review on translation from conventional analysis to field-portable sensor
- 2021
-
Ingår i: Trends in Food Science & Technology. - : ELSEVIER SCIENCE LONDON. - 0924-2244 .- 1879-3053. ; 109, s. 674-689
-
Forskningsöversikt (refereegranskat)abstract
- Background: In recent decades, contaminations with heavy metals ions have adversely affected the environment, food safety, and human health. Heavy metals, leaching to water sources from the industrial effluents, can enter into the aquatic and food chains of humans and animals from a variety of anthmpogenic sources. Scope and Approach: Heavy metal detection has been an intensive area of research today. Both laboratory-based analytical instruments and innovative sensor devices like the electronic nose, electronic tongue, and bio/ chemical sensors have increasingly emerged to meet the demand for legislative actions on environmental pollution control and early warning. These evolving technology and developments particularly in the area of nanotechnology and sensors have become key contributing factors in heavy metal detection. Key Findings and Conclusions: This endeavor aims at exploring this field in detail to understand the key principles behind this flourishing science and summarize the recent development in heavy metal detection technologies. This article also gives a brief review of commercially available portable devices that has the potential to become the next gold standard instruments in heavy metal detection.
|
|
| 3. |
- Caron, Bénédicte, et al.
(författare)
-
IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis : the PROCTRIAL Consensus
- 2022
-
Ingår i: Clinical Gastroenterology and Hepatology. - : Elsevier. - 1542-3565 .- 1542-7714. ; 20:11, s. 2169-2627.e1
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND AND AIMS: Clinical trials evaluating biologics and small molecules in patients with ulcerative colitis are predominantly excluding ulcerative proctitis. The objective of the PROCTRIAL (Definition and endpoints for ulcerative PROCtitis in clinical TRIALs) initiative was to develop consensus statements for definitions, inclusion criteria, and endpoints for the evaluation of ulcerative proctitis in adults.METHODS: Thirty-five international experts held a consensus meeting to define ulcerative proctitis, and the endpoints to use in clinical trials. Based on a systematic review of the literature, statements were generated, discussed, and approved by the working group participants using a modified Delphi method. Consensus was defined as at least 75% agreement among voters.RESULTS: The group agreed that the diagnosis of ulcerative proctitis should be made by ileocolonoscopy and confirmed by histopathology, with the exclusion of infections, drug-induced causes, radiation, trauma, and Crohn's disease. Ulcerative proctitis was defined as macroscopic extent of lesions limited to 15 cm distance from the anal verge in adults. Primary and secondary endpoints were identified to capture response of ulcerative proctitis to therapy. A combined clinical and endoscopic primary endpoint for the evaluation of ulcerative proctitis disease activity is proposed. Secondary endpoints which should be evaluated include endoscopic remission, histological remission, mucosal healing, histologic endoscopic mucosal improvement, disability, fecal incontinence, urgency, constipation, and health-related quality of life.CONCLUSION: In response to the need for guidance on the design of clinical trials in patients with ulcerative proctitis, the PROCTRIAL consensus provides recommendations on the definition and endpoints for ulcerative proctitis clinical trials.
|
|
| 4. |
- D'Amico, Ferdinando, et al.
(författare)
-
Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD) : A Global Survey and an International Delphi Consensus
- 2023
-
Ingår i: Journal of Clinical Medicine. - : MDPI. - 2077-0383. ; 12:19
-
Tidskriftsartikel (refereegranskat)abstract
- As the patents for biologic originator drugs expire, biosimilars are emerging as cost-effective alternatives within healthcare systems. Addressing various challenges in the clinical management of inflammatory bowel disease (IBD) remains crucial. To shed light on physicians' current knowledge, beliefs, practical approaches, and concerns related to biosimilar adoption-whether initiating a biosimilar, transitioning from an originator to a biosimilar, or switching between biosimilars (including multiple switches and reverse switching)-a global survey was conducted. Fifteen physicians with expertise in the field of IBD from 13 countries attended a virtual international consensus meeting to develop practical guidance regarding biosimilar adoption worldwide, considering the survey results. This consensus centered on 10 key statements covering biosimilar effectiveness, safety, indications, rationale, multiple switches, therapeutic drug monitoring of biosimilars, non-medical switching, and future perspectives. Ultimately, the consensus affirmed that biosimilars are equally effective and safe when compared to originator drugs. They are considered suitable for both biologic-naïve patients and those who have previously been treated with originator drugs, with cost reduction being the primary motivation for transitioning from an originator drug to a biosimilar.
|
|
| 5. |
- King, James A., et al.
(författare)
-
Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries : a population-based study of countries in the Organisation for Economic Co-operation and Development
- 2019
-
Ingår i: The Lancet Gastroenterology & Hepatology. - : Elsevier. - 2468-1253. ; 4:4, s. 287-295
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Hospitalisation rates for inflammatory bowel disease (IBD) vary across the world. We aimed to investigate temporal patterns of hospitalisation for IBD in member countries of the Organisation for Economic Co-operation and Development (OECD).Methods: From the OECD database, we assessed IBD-related hospitalisation rates (expressed as annual rates per 100 000 inhabitants) for 34 countries from 1990 to 2016. We calculated mean hospitalisation rates for the period 2010-15 and used joinpoint regression models to calculate average annual percentage changes with 95% CIs.Findings: Mean hospitalisation rates for IBD from 2010 to 2015 were highest in North America (eg, 33.9 per 100 000 in the USA), Europe (eg, 72.9 per 100 000 in Austria), and Oceania (eg, 31.5 per 100 000 in Australia). Hospitalisation rates for IBD were stabilising or decreasing over time in many countries in these regions but increasing in others. Countries in Asia and Latin America and the Caribbean had the lowest IBD-related hospitalisation rates but the greatest increases in rates over time. For example, Turkey had an annual hospitalisation rate of 10.8 per 100 000 inhabitants and an average annual percentage change of 10.4% (95% CI 5.2-15.9). Similarly, Chile had an annual hospitalisation rate of 9.0 per 100 000 inhabitants and an average annual percentage change of 5.9% (4.9-7.0).Interpretation: Hospitalisation rates for IBD are high in western countries but are typically stabilising or decreasing, whereas rates in many newly industrialised countries are rapidly increasing, which reflects the known increase in IBD prevalence in these countries. Potential explanations for these trends include changes in the epidemiology of IBD, health-care delivery, and infrastructure in these countries, as well as overall country-specific patterns in hospitalisations and differences between countries in data collection methods.
|
|
